Castroville, CA – According to filings with the U.S. Securities and Exchange Commission, Biopharmaceutical Research is raising $23,156,923.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, George Hodgin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biopharmaceutical Research
BRC is a pharmaceutical manufacturing and analytical firm focused on the production of cannabis for researchers across the United States and the USDA-compliant THC testing of hemp. We are a DEA-approved laboratory. Our mission is to develop federally compliant, active pharmaceutical ingredients for plant-based therapeutics, with uncompromising quality, for patients and researchers everywhere.

To learn more about Biopharmaceutical Research, visit http://www.biopharmaresearchco.com/

Contact:
George Hodgin, Chief Executive Officer
831-632-0913
ghodgin@biopharmaresearchco.com
https://www.linkedin.com/in/georgehodgin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved